COPD pathophysiology and diagnosis

COPD Pathophysiology - The Inflamed Airway

• Chronic inflammation triggered by noxious particles (tobacco smoke, pollution) recruits key inflammatory cells: neutrophils, macrophages, and CD8+ T-cells.
• This leads to two core pathologic processes:
  • Parenchymal Destruction (Emphysema): An imbalance of ↑proteases (like neutrophil elastase) and ↓antiproteases (like α1-antitrypsin) destroys alveolar walls, causing loss of elastic recoil.
  • Small Airway Disease: Inflammation and oxidative stress lead to goblet cell hyperplasia (chronic bronchitis) and peribronchiolar fibrosis, which narrows the airway.

⭐ The primary site of airflow limitation in early COPD is the small conducting airways (<2 mm in diameter), often preceding significant alveolar destruction.

COPD Diagnosis - The Breathless Patient

• Clinical Suspicion: Based on symptoms (progressive dyspnea, chronic cough, sputum) & risk factor exposure (tobacco smoke, occupational dusts).

  • History: >20 pack-year smoking history is a classic risk.
  • Exam findings: Barrel chest, pursed-lip breathing, decreased breath sounds.

• Spirometry: Gold standard for diagnosis. Must be performed post-bronchodilator.

  • Diagnostic Hallmark: Fixed airflow obstruction with FEV1/FVC < 0.70.

⭐ In young patients (<45 years) or non-smokers with a family history, screen for Alpha-1 Antitrypsin (AAT) deficiency, which causes basilar-predominant emphysema.

COPD Staging - The GOLD Standard

• Staging begins after a post-bronchodilator FEV1/FVC < 0.70 confirms diagnosis. Airflow limitation severity (spirometric grade) is based on FEV1:

  • GOLD 1 (Mild): FEV1 ≥ 80% predicted
  • GOLD 2 (Moderate): 50% ≤ FEV1 < 80%
  • GOLD 3 (Severe): 30% ≤ FEV1 < 50%
  • GOLD 4 (Very Severe): FEV1 < 30%

• The refined ABCD assessment tool guides therapy by combining symptom burden (mCAT/CCQ scores) with exacerbation risk.

⭐ Treatment decisions are primarily guided by the patient's ABCD assessment group, not the spirometric grade alone.

High‑Yield Points - ⚡ Biggest Takeaways

• COPD is characterized by persistent, irreversible airflow limitation, with cigarette smoking as the number one risk factor.
• The core pathophysiology involves a protease-antiprotease imbalance, leading to alveolar destruction (emphysema).
• Spirometry is required for diagnosis, confirming a post-bronchodilator FEV1/FVC ratio < 0.7.
• Suspect α1-antitrypsin deficiency in young patients (<45 years) with panacinar emphysema and no smoking history.
• Unlike asthma, the airflow obstruction is not fully reversible with bronchodilators.